公开(公告)号：US20140093523A1

公开(公告)日：2014-04-03

申请号：US14096767

申请日：2013-12-04

Applicant: Immunogen, Inc. ,  Janssen Biotech, Inc.

Inventor： Qiming Chen ,  Mohit Trikha ,  Robert J. Lutz ,  Rita M. Steeves ,  Godfrey Amphlett

IPC: A61K47/48

CPC classification number: A61K47/6803 ,  A61K47/6849 ,  A61K2039/505 ,  C07K16/2839 ,  C07K2317/21 ,  C07K2317/73

Abstract: The invention relates to conjugates of anti-integrin specific antibodies with cytotoxic compounds, the synthesis, selection, and use of such conjugates for use in cancer therapy or other diseases mediated by cell proliferation, cell migration, or inflammation and which pathology involves angiogenesis or neovascularization of new tissue. In addition the invention relates to combination therapy of such diseases wherein the treatment comprises use of said conjugates in combination with one or more other treatment modalities including but not limited to: chemotherapy, surgery or radiation therapy. The preferred conjugates contain maytansinoid compounds linked to the antibody by a disulfide linkage, and preferred chemotherapeutic agents are doxorubicin, a taxane, a camptothecin, a podophyllotoxin, a nucleoside analog, or a pyrimidine analog.

Abstract translation: 本发明涉及抗整联蛋白特异性抗体与细胞毒性化合物的缀合物，用于癌症治疗或由细胞增殖，细胞迁移或炎症介导的其它疾病的这种缀合物的合成，选择和使用以及哪些病理学涉及血管生成或新生血管形成 的新组织。 此外，本发明涉及这些疾病的组合治疗，其中治疗包括使用所述缀合物与一种或多种其它治疗方式的组合，包括但不限于化疗，手术或放射治疗。 优选的缀合物含有通过二硫键与抗体连接的美登木素生物碱化合物，优选的化学治疗剂是多柔比星，紫杉烷，喜树碱，鬼臼毒素，核苷类似物或嘧啶类似物。

公开(公告)号：US20140141013A1

公开(公告)日：2014-05-22

申请号：US14167384

申请日：2014-01-29

Applicant: Janssen Biotech, Inc.

Inventor： Jill Giles-Komar ,  David M. Knight ,  David Peritt ,  Mohit Trikha

IPC: C07K16/24

CPC classification number: C07K16/248 ,  A01K67/0271 ,  A01K2267/0331 ,  A61K39/3955 ,  A61K2039/505 ,  C07K16/4241 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

Abstract: The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

Abstract translation: 本发明涉及至少一种衍生自鼠CLB-8抗体的新型嵌合，人源化或CDR移植的抗IL-6抗体，包括编码至少一种这样的抗IL-6抗体的分离的核酸，载体， 宿主细胞，转基因动物或植物，以及其制备和使用方法，包括治疗组合物，方法和装置。